or Try an Advanced Search...

    Technical Analysis for TLX - Telix Pharmaceuticals Ltd  

    Grade Last Price % Change Price Change
    A 15.090 -2.71% -0.420
    TLX closed up 4.02 percent on Monday, April 29, 2024, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical TLX trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing High Bullish -2.71%
    New Uptrend Bullish -2.71%
    Pocket Pivot Bullish Swing Setup -2.71%
    New 52 Week High Strength -2.71%
    Upper Bollinger Band Walk Strength -2.71%
    Wide Bands Range Expansion -2.71%
    Above Upper BB Strength -2.71%
    Overbought Stochastic Strength -2.71%
    Up 3 Days in a Row Strength -2.71%
    Upper Bollinger Band Touch Strength -2.71%
    Older End-of-Day Signals for TLX ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR about 3 hours ago
    Down 3% about 3 hours ago
    Down 2% about 6 hours ago
    Down 1% about 6 hours ago
    Rose Above Previous Day's High about 7 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    TLX Chart by TradingView
    Basic chart:

    Profile

    Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The Company's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Natural Sciences Medicine Pharmaceutical Cancer Radio Drugs Pharmaceuticals Biopharmaceutical Therapeutic Product Profile Therapeutic Products Radiation Prostate Cancer Radiation Therapy Radiopharmaceuticals Brain Cancer Glioblastoma Radioactivity Radiopharmaceutical

    Is TLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 17 Q1 2024 Revenue and Business Update
    Apr 16 QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
    Apr 15 TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
    Apr 11 Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
    Mar 26 World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
    Mar 18 QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
    Mar 18 QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy
    Mar 11 Appointment of Dr Darren Patti to Group Chief Operating Officer
    Mar 4 Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
    Feb 26 Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
    See more TLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.55
    52 Week Low 8.2
    Average Volume 1,221,446
    200-Day Moving Average 10.902
    50-Day Moving Average 12.331
    20-Day Moving Average 13.142
    10-Day Moving Average 13.783
    Average True Range 0.536
    RSI (14) 79.08
    ADX 25.02
    +DI 46.325
    -DI 14.329
    Chandelier Exit (Long, 3 ATRs) 13.942
    Chandelier Exit (Short, 3 ATRs) 13.428
    Upper Bollinger Bands 15.121
    Lower Bollinger Band 11.162
    Percent B (%b) 1.1
    BandWidth 30.126
    MACD Line 0.710
    MACD Signal Line 0.452
    MACD Histogram 0.2572
    Fundamentals Value
    Market Cap 4.28 Billion
    Num Shares 276 Million
    EPS -0.09
    Price-to-Earnings (P/E) Ratio -174.27
    Price-to-Sales 214.62
    Price-to-Book 14.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 16.455
    Resistance 3 (R3) 16.363 15.957 16.298
    Resistance 2 (R2) 15.957 15.716 16.003 16.245
    Resistance 1 (R1) 15.733 15.567 15.845 15.825 16.192
    Pivot Point 15.327 15.327 15.383 15.373 15.327
    Support 1 (S1) 15.103 15.086 15.215 15.195 14.828
    Support 2 (S2) 14.697 14.937 14.743 14.775
    Support 3 (S3) 14.473 14.697 14.723
    Support 4 (S4) 14.565